Chugai Pharma Q3 Earnings Rise On Sales Growth; FY26 Outlook Unchanged

What happened

Chugai Pharmaceutical reported revenue of JPY 1,068.1 billion for the nine months ended September 30, 2026, up 17.2% from a year earlier. Operating profit rose 21.6% to JPY 522.6 billion and net income grew 22.8% to JPY 375.3 billion, while the full-year 2026 outlook stayed unchanged.

Confirmed

Global impact / market context

Higher sales of key drugs and more royalty income, which means payments received when other companies sell Chugai-linked medicines, lifted profit despite rising research costs. Unchanged guidance signals management expects the trend to hold, supporting future spending on late-stage studies.

Analyst inference

The stock traded at JPY 6,688, down 3.03%. Roche owns about 59.89% of shares, which means most voting power sits with one holder and the free float available to outside investors is comparatively small, potentially amplifying price moves.

Analyst inference

What to watch

1. Full-year 2026 targets remain revenue of JPY 1,345 billion, Core operating profit of JPY 670 billion and Core net income of JPY 485 billion, with core meaning adjusted figures the company highlights. Confirmed
2. Watch whether global Phase 3 studies in non-small cell lung cancer, multiple myeloma, hemophilia A and obesity advance, since later-stage trials typically require more capital spending before any revenue arrives. Proposed
3. Track research and development costs and royalty income, because rising trial spending can pressure profit while royalty streams from partners such as Roche directly add high-margin revenue with little added cost. Analyst inference

Evidence

• Original source link unavailable